02 February 2024
02 February 2024
The company has received clearance to start the Phase III trial in patients with stage III/IV non-small cell lung cancer (NSCLC) with uncommon EGFR mutation.
The trial will analyse the efficacy and safety of AVD-104 versus avacincaptad pegol to treat GA.
In preclinical studies, RSO-021 showed to kill malignant cells by increasing oxidative stress.
The trial will analyse tezampanel as a treatment for opiate withdrawal.
The Phase I trial is set to commence in the first half of this year.
The neuromodulation device is being evaluated for chronic pain management, with initial targets set on lumbar peripheral nerve stimulation.
The French Government grant will cover preclinical and clinical research for Vivet’s gene therapy for cerebrotendinous xanthomatosis.
Synergy Spine Solutions will use the proceeds from the round to continue development of Synergy Disc and apply for a pre-market approval from the US Food and Drug Administration (FDA).
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
